Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vivek G Nayak"'
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Ramakrishnan Melarkode, Sumit Kumar Jha, Narendra Chirmule, Anita U. Rao, Shilpa G Ramaswamy, Vishika Hegde, Vinit S. Waichale, Nilanjan Sengupta, Vivek G Nayak
Publikováno v:
Bioanalysis. 9:975-986
Aim: Tregopil, a novel PEGylated human insulin is in clinical development for oral delivery in diabetes treatment. The aim of the study was to develop and validate a sensitive and specific ELISA method for quantitating Tregopil in diabetes subjects o
Autor:
Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien